Chaudhary Suman, Kanwar Rupinder Kaur, Kanwar Jagat Rakesh
Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research, (NLIMBR), School of Medicine (SoM), Centre for Molecular and Medical Research (C-MMR) Strategic Research Centre, Faculty of Health, Deakin University, Waurn Ponds, Victoria 3217. Australia.
Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), Centre for Molecular and Medical Research (C-MMR), School of Medicine (SoM), Faculty of Health, Deakin University, Waurn Ponds, Victoria 3217. Australia.
Curr Top Med Chem. 2017 Jun 7;17(18):2100-2111. doi: 10.2174/1568026617666170130110021.
Targeted therapeutics is a new generation therapy that can increase the efficacy of chemotherapeutic drugs, by facilitating site-specific delivery with minimum off-target effects. Amongst the targeted therapy, nucleic-acid based aptamers are increasingly gaining interest due to their small size, long shelf-life and ease in synthesis. Further, lactoferrin, a milk protein belonging to the transferrin family is now an established multi-functional iron-binding protein. Its applicability as an immunomodulator, antimicrobial and an anti-cancer agent has made this protein highly valuable. Recent research has been focusing towards increasing the efficacy of lactoferrin by encapsulating them in novel nanoparticles, that facilities in providing their controlled and sustained release. This review focuses on the application of aptamers against solid tumors, specifically colorectal cancer (CRC) indicating the different anti-cancer targeted strategies to target anti-angiogenic vascular endothelial growth factor -A (VEGF-A) and epidermal growth factor receptor (EGFR) signalling. Additionally, it highlights the synergistic approach of functionalising aptamers with drug loaded nanoparticles to facilitate enhanced uptake, stability and increase in the retention time. Special emphasis is given on lactoferrin loaded aptamer functionalised nanoparticles as anticancer drug delivery systems. Apart from highlighting the role of these aptamernanocarriers in tumor specific targeting and induction of apoptosis, there applicability in nanotheranostics, involving detection, diagnosis and treatment is also discussed here.
靶向治疗是新一代的治疗方法,它可以通过促进药物在特定部位的递送并使脱靶效应最小化来提高化疗药物的疗效。在靶向治疗中,基于核酸的适配体因其尺寸小、保质期长和易于合成而越来越受到关注。此外,乳铁蛋白是转铁蛋白家族的一种乳蛋白,现在是一种公认的多功能铁结合蛋白。它作为免疫调节剂、抗菌剂和抗癌剂的适用性使这种蛋白质具有很高的价值。最近的研究一直致力于通过将乳铁蛋白包裹在新型纳米颗粒中来提高其疗效,这有助于实现其可控和持续释放。本综述重点介绍了适配体在实体瘤,特别是结直肠癌(CRC)中的应用,阐述了针对抗血管生成血管内皮生长因子-A(VEGF-A)和表皮生长因子受体(EGFR)信号传导的不同抗癌靶向策略。此外,它还强调了将适配体与载药纳米颗粒功能化的协同方法,以促进增强摄取、稳定性并延长保留时间。特别强调了负载乳铁蛋白的适配体功能化纳米颗粒作为抗癌药物递送系统的作用。除了突出这些适配体纳米载体在肿瘤特异性靶向和诱导细胞凋亡中的作用外,还在此讨论了它们在纳米诊疗中的适用性,包括检测、诊断和治疗。